JP2017500289A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500289A5 JP2017500289A5 JP2016531049A JP2016531049A JP2017500289A5 JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5 JP 2016531049 A JP2016531049 A JP 2016531049A JP 2016531049 A JP2016531049 A JP 2016531049A JP 2017500289 A5 JP2017500289 A5 JP 2017500289A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- amino
- acetyl
- hpyy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 58
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 33
- -1 PYY compound Chemical class 0.000 claims 32
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 30
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 claims 15
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- VNWXCGKMEWXYBP-YFKPBYRVSA-N (3s)-3-amino-6-(diaminomethylideneamino)hexanoic acid Chemical compound OC(=O)C[C@@H](N)CCCNC(N)=N VNWXCGKMEWXYBP-YFKPBYRVSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 0 *C([C@@](CCCCNC(*OCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)NC(CC[C@@](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)N*)=O Chemical compound *C([C@@](CCCCNC(*OCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)NC(CC[C@@](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)N*)=O 0.000 description 1
- XCWVXTGEFYFFQZ-FHBSJOOWSA-N CC1(CC(N[C@@H](Cc(cc2)ccc2O)C(N)=O)=O)C(CCNC(N)N)C1 Chemical compound CC1(CC(N[C@@H](Cc(cc2)ccc2O)C(N)=O)=O)C(CCNC(N)N)C1 XCWVXTGEFYFFQZ-FHBSJOOWSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13193080 | 2013-11-15 | ||
| EP13193080.2 | 2013-11-15 | ||
| US201361906022P | 2013-11-19 | 2013-11-19 | |
| US61/906,022 | 2013-11-19 | ||
| PCT/EP2014/074477 WO2015071356A1 (en) | 2013-11-15 | 2014-11-13 | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500289A JP2017500289A (ja) | 2017-01-05 |
| JP2017500289A5 true JP2017500289A5 (enExample) | 2017-12-07 |
| JP6629198B2 JP6629198B2 (ja) | 2020-01-15 |
Family
ID=49582656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531049A Active JP6629198B2 (ja) | 2013-11-15 | 2014-11-13 | ３５位にβ−ホモアルギニン置換を有するＨＰＹＹ（１−３６） |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10583172B2 (enExample) |
| EP (1) | EP3068795B1 (enExample) |
| JP (1) | JP6629198B2 (enExample) |
| CN (1) | CN105764919B (enExample) |
| WO (1) | WO2015071356A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2651398T (lt) | 2010-12-16 | 2018-03-26 | Novo Nordisk A/S | Kietos kompozicijos, apimančios glp-1 agonistą ir n-(8-(2-hidroksibenzoil)amino)oktano rūgšties druską |
| RS57727B1 (sr) | 2012-03-22 | 2018-12-31 | Novo Nordisk As | Kompozicije glp-1 peptida i njihovo dobijanje |
| PL2991671T3 (pl) | 2013-05-02 | 2019-01-31 | Novo Nordisk As | Doustne dawkowanie związków glp-1 |
| CA2929672A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MA43205A (fr) * | 2015-06-12 | 2018-09-19 | Novo Nordisk As | Composés pyy sélectifs et leurs utilisations |
| ES2828526T3 (es) | 2016-11-07 | 2021-05-26 | Novo Nordisk As | Esteres activos DCHBS de compuestos PEG y sus usos |
| PL3746111T3 (pl) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową |
| GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| US20220280611A1 (en) * | 2019-08-07 | 2022-09-08 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid |
| CR20220206A (es) * | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| AU2022210988B9 (en) | 2021-01-20 | 2024-02-22 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2022347024A1 (en) | 2021-09-15 | 2024-05-02 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08510205A (ja) | 1993-03-29 | 1996-10-29 | ユニバーシティ オブ シンシナティ | Ｙｙペプチドのアナログとその用途 |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| CA2271788A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| PE20000564A1 (es) | 1998-06-08 | 2000-07-05 | Schering Corp | Antagonistas receptores y5 de neuropeptidos |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| BR0116206A (pt) | 2000-12-14 | 2003-12-23 | Amylin Pharmaceuticals Inc | Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos |
| US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
| KR100989647B1 (ko) | 2001-09-24 | 2010-10-26 | 오레곤 헬스 앤드 사이언스 유니버시티 | 식습관의 변화 |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| WO2004066966A2 (en) | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005058958A2 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
| NZ579621A (en) | 2004-02-11 | 2011-03-31 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
| JP5638177B2 (ja) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド |
| MXPA06010346A (es) | 2004-03-17 | 2007-04-23 | 7Tm Pharma As | Agonistas de receptor selectivo de y2/y4 para intervenciones terapeuticas. |
| CN1953763A (zh) | 2004-03-17 | 2007-04-25 | 7Tm制药联合股份有限公司 | 用于治疗性干预的y4选择性受体激动剂 |
| PL2060266T3 (pl) | 2004-03-17 | 2012-01-31 | 7Tm Pharma As | Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych |
| EA011860B1 (ru) | 2004-03-17 | 2009-06-30 | 7ТиЭм ФАРМА А/С | Селективные агонисты рецептора y2 для терапевтического воздействия |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CN101005857A (zh) | 2004-07-08 | 2007-07-25 | 诺和诺德公司 | 多肽延长标记 |
| US7994119B2 (en) | 2004-07-19 | 2011-08-09 | University Of Cincinnati | Compounds for control of appetite |
| WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JP2009500453A (ja) | 2005-07-11 | 2009-01-08 | ナステック ファーマスーティカル カンパニー インク． | 向上されたｐｙｙの粘膜送達用製剤 |
| RU2008100218A (ru) | 2005-07-18 | 2009-08-27 | Ново Нордикс А/С (Dk) | Пептиды для лечения ожирения |
| CA2623094A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| AU2005337116A1 (en) * | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
| CA2630649A1 (en) | 2005-12-07 | 2007-06-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor-agonists |
| JP2009519296A (ja) | 2005-12-14 | 2009-05-14 | ノボ・ノルデイスク・エー／エス | ポリペプチド延長タグ |
| US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
| EP2004238A2 (en) | 2006-03-21 | 2008-12-24 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
| JP2010516652A (ja) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー／エス | 肥満の治療に使用される新規ペプチド |
| US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
| GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
| EP2500432A3 (en) | 2007-07-09 | 2012-12-19 | Imperial Innovations Limited | Analogues of human pancreatic polypeptide (hPP) and their effects on feeding behaviours |
| CN101842109B (zh) | 2007-09-05 | 2014-01-29 | 诺沃-诺迪斯克有限公司 | 用a-b-c-d-衍生的肽和它们的治疗用途 |
| US20100204113A1 (en) | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of stresscopin-related peptide as a therapeutic agent |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| MX2010011845A (es) * | 2008-05-16 | 2010-11-22 | Novo Nordisk As | Agonistas del receptor y2 y/o y4 de larga accion. |
| US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
| AU2009312892A1 (en) | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2-receptor (Y-2r) agonists and uses thereof |
| AU2010216372B2 (en) | 2009-02-20 | 2013-06-20 | Ipsen Pharma S.A.S. | Cytotoxic conjugates having neuropeptide Y receptor binding compound |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
| EP2498800A1 (en) | 2009-11-13 | 2012-09-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| WO2011131646A1 (en) | 2010-04-20 | 2011-10-27 | Novo Nordisk A/S | Long-acting gastrin derivatives |
| PT2566469T (pt) | 2010-05-05 | 2023-01-10 | Boehringer Ingelheim Int | Terapia de combinação |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| US20150141336A1 (en) | 2012-05-29 | 2015-05-21 | Novo Nordisk A/S | Pancreatic Peptide Compounds and Use |
| EP2992008B1 (en) | 2013-05-02 | 2019-04-10 | GlaxoSmithKline Intellectual Property Development Limited | Therapeutic peptides |
| CA2929672A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MA43205A (fr) | 2015-06-12 | 2018-09-19 | Novo Nordisk As | Composés pyy sélectifs et leurs utilisations |
-
2014
- 2014-11-13 US US15/036,509 patent/US10583172B2/en active Active
- 2014-11-13 WO PCT/EP2014/074477 patent/WO2015071356A1/en not_active Ceased
- 2014-11-13 EP EP14802834.3A patent/EP3068795B1/en active Active
- 2014-11-13 CN CN201480062212.0A patent/CN105764919B/zh active Active
- 2014-11-13 JP JP2016531049A patent/JP6629198B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500289A5 (enExample) | ||
| JP2017505284A5 (enExample) | ||
| RU2017145348A (ru) | Селективные соединения пептида yy и их применения | |
| JP2018522843A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013533227A5 (enExample) | ||
| JP2015517459A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2013519675A5 (enExample) | ||
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| JP2016006096A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015513544A5 (enExample) | ||
| WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
| WO2015128403A3 (en) | An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| JP2016539921A5 (enExample) | ||
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| WO2015095354A3 (en) | Compositions and methods for treating fatty tissue buildup | |
| JP2011046708A5 (enExample) | ||
| JP2010518061A5 (enExample) | ||
| JP2017522300A5 (enExample) | ||
| JP2015514781A5 (enExample) | ||
| WO2014071405A3 (en) | Long-acting single-chain insulin analogues | |
| JP2015516419A5 (enExample) |